This application proposes research development of a clinical psychologist with interests and expertise in the control of chemotherapy side effects using a biobehavioral approach. Anticipatory neusea and vomiting are significant side effects that develop in approximately 25% of patients receiving chemotherapy treatment for cancer. Converging lines of evidence from psychologic, pharmacologic and neurologic investigations suggest that anticipatory nausea/vomiting are learned or conditioned behaviors. Adequate control of chemotherapy side effects such as anticipatory nausea and vomiting is essential for maximizing cancer treatment effectiveness. Proposed research is directed toward optimizing currently available behavioral interventions for side effect control, developing a new technology for nausea assessment and an increased understanding of side effect etiology. To achieve these aims, the following career development activities designed to enhance systematic, integrated studies of side effect control are proposed: (1) randomized clinical trials to assess whether the biobehavioral treatment of systematic desensitization is as effective when done by oncologists and oncology nurses as it is when done by behavioral psychologists; (2) development and refinement of ambulatory physiologic monitoring for concomitants of patient-reported nausea; and (3) prospective studies on the etiology of anticipatory side effects to test the ability of an 8-question screening instrument given after a patient's first chemotherapy treatment to predict the development of anticipatory side effects. The research has anticipated long-term benefits in the improvement of patient compliance for both current treatment and randomized treatment research trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Modified Research Career Development Award (K04)
Project #
Application #
Study Section
Behavioral Medicine Study Section (BEM)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
School of Medicine & Dentistry
United States
Zip Code
Hoon, D S; Kuo, C T; Wascher, R A et al. (2001) Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 117:375-8
Taback, B; Morton, D L; O'Day, S J et al. (2001) The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 158:78-92
Sobrin, L; Liu, Z; Monroy, D C et al. (2000) Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 41:1703-9
Hoon, D S; Bostick, P; Kuo, C et al. (2000) Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 60:2253-7
Fujiwara, Y; Hoon, D S (2000) Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe. Int J Oncol 17:783-7
Okamoto, T; Irie, R F; Fujii, S et al. (1998) Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 111:1034-9
Kuo, C T; Bostick, P J; Irie, R F et al. (1998) Assessment of messenger RNA of beta 1-->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma. Clin Cancer Res 4:411-8
O'Connell, C D; Juhasz, A; Kuo, C et al. (1998) Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. Clin Chem 44:1161-9
Chi, D D; Merchant, R E; Rand, R et al. (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150:2143-52
Sarantou, T; Chi, D D; Garrison, D A et al. (1997) Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57:1371-6

Showing the most recent 10 out of 20 publications